These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease. McKinney M; Coyle JT Mayo Clin Proc; 1991 Dec; 66(12):1225-37. PubMed ID: 1749291 [TBL] [Abstract][Full Text] [Related]
7. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. Lawrence AD; Sahakian BJ Neurochem Res; 1998 May; 23(5):787-94. PubMed ID: 9566619 [TBL] [Abstract][Full Text] [Related]
8. Cholinergic strategies in the treatment of Alzheimer's disease. Davidson M; Stern RG; Bierer LM; Horvath TB; Zemishlani Z; Markofsky R; Mohs RC Acta Psychiatr Scand Suppl; 1991; 366():47-51. PubMed ID: 1897375 [TBL] [Abstract][Full Text] [Related]
10. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. Francis PT; Palmer AM; Sims NR; Bowen DM; Davison AN; Esiri MM; Neary D; Snowden JS; Wilcock GK N Engl J Med; 1985 Jul; 313(1):7-11. PubMed ID: 2582256 [TBL] [Abstract][Full Text] [Related]
11. Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Ebert U; Kirch W Eur J Clin Invest; 1998 Nov; 28(11):944-9. PubMed ID: 9824440 [TBL] [Abstract][Full Text] [Related]
12. Regional brain metabolic responsivity to the muscarinic cholinergic agonist arecoline is similar in young and aged Fischer-344 rats. Soncrant TT; Holloway HW; Greig NH; Rapoport SI Brain Res; 1989 May; 487(2):255-66. PubMed ID: 2731046 [TBL] [Abstract][Full Text] [Related]
13. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Garcia-Alloza M; Gil-Bea FJ; Diez-Ariza M; Chen CP; Francis PT; Lasheras B; Ramirez MJ Neuropsychologia; 2005; 43(3):442-9. PubMed ID: 15707619 [TBL] [Abstract][Full Text] [Related]
14. Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT). Wettstein A; Spiegel R Psychopharmacology (Berl); 1984; 84(4):572-3. PubMed ID: 6441959 [TBL] [Abstract][Full Text] [Related]
15. Treatment strategies for the cognitive deficits of Alzheimer's disease. Meador KJ J S C Med Assoc; 1994 Nov; 90(11):543-7. PubMed ID: 7853858 [No Abstract] [Full Text] [Related]
16. The cholinergic system in aging and neuronal degeneration. Schliebs R; Arendt T Behav Brain Res; 2011 Aug; 221(2):555-63. PubMed ID: 21145918 [TBL] [Abstract][Full Text] [Related]
17. Challenging assumptions about Alzheimer's disease: mild cognitive impairment and the cholinergic hypothesis. Morris JC Ann Neurol; 2002 Feb; 51(2):143-4. PubMed ID: 11835369 [No Abstract] [Full Text] [Related]
18. Impairment of basal forebrain cholinergic neurons associated with aging and long-term loss of ovarian function. Gibbs RB Exp Neurol; 1998 Jun; 151(2):289-302. PubMed ID: 9628764 [TBL] [Abstract][Full Text] [Related]
19. Microdosing of scopolamine as a "cognitive stress test": rationale and test of a very low dose in an at-risk cohort of older adults. Snyder PJ; Lim YY; Schindler R; Ott BR; Salloway S; Daiello L; Getter C; Gordon CM; Maruff P Alzheimers Dement; 2014 Mar; 10(2):262-7. PubMed ID: 24698030 [TBL] [Abstract][Full Text] [Related]